RT Journal Article
SR Electronic
T1 A Rapid review on the COVID-19 Pandemic’s Global Impact on Breast Cancer Screening Participation Rates and Volumes from January-December 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.06.23285513
DO 10.1101/2023.02.06.23285513
A1 Lee, Reagan
A1 Xu, Wei
A1 Dozier, Marshall
A1 McQuillan, Ruth
A1 Theodoratou, Evropi
A1 Figueroa, Jonine D.
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/02/06/2023.02.06.23285513.abstract
AB Background COVID-19 has strained population breast mammography screening programs that aim to diagnose and treat breast cancers earlier. As the pandemic has affected countries differently, we aimed to quantify changes in breast screening volume and uptake during the first year of the COVID-19 pandemic.Methods We systematically searched Medline, the WHO (World Health Organization) COVID-19 database, and governmental databases. Studies covering January 2020 to March 2022 were included. We extracted and analyzed data regarding study methodology, screening volume and uptake. To assess for risk-of-bias, we used the Joanna Briggs Institute Critical Appraisal tool.Results Twenty-six cross-sectional descriptive studies were included out of 935 independent records. Reductions in screening volume and uptake rates were observed among eight countries. Changes in screening participation volume in five countries with national population-based screening ranged from -13% to –31%. Among two countries with limited population-based programs the decline ranged from -61% to -41%. Within the USA, population participation volumes varied ranging from +18% to -39% with suggestion of differences by insurance status (HMO, Medicare, and low-income programs). Almost all studies had high risk-of-bias due to insufficient statistical analysis and confounding factors.Discussion and Conclusion Extent of COVID-19-induced reduction in breast screening participation volume differed by region and data suggested potential differences by healthcare setting (e.g., national health insurance vs private health care). Recovery efforts should monitor access to screening and early diagnosis to determine if prevention services need strengthening to increase coverage of marginalized groups and reduce disparities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementET is supported by a Cancer Research UK Career Development Fellowship (C31250/A22804) JDF is investigator at the National Cancer Institute and this work is funded in part by the IRP of the NCI/NIHAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll data analysed is provided in the manuscript or supplements